Completed PHASE4 INTERVENTIONAL NCT00090012

Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder

The Comparison of Efficacy and Safety of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder

Sponsor: Eli Lilly and Company

Conditions Schizoaffective Disorder Schizophrenia

Interventions Olanzapine Quetiapine

Updated 6 times since 2017 Last updated: Nov 5, 2007 Started: Jul 31, 2004 Completion: Mar 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Schizoaffective Disorder and Schizophrenia and is currently completed. Eli Lilly and Company leads this study, which shows 6 recorded versions since 2004 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jul 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Brooklyn, United States , Clementon, United States , Cleveland, United States , Conroe, United States , Detroit, United States , Garden Grove, United States , Granite City, United States , Kenilworth, United States , La Mesa, United States and 15 more locations